Lotus Ventures Inc. (CSE:J, FRA:LV9) (the “Company” or “Lotus”) has completed the commissioning of its Armstrong facility and expects its initial harvest in September 2019. As the Company prepares for a busy fall season, we would like to provide our objectives for 2019, heading into 2020.

Initial Harvest:

Lotus initially brought 75 live plants (the “Plants”) into the facility as per its press release dated May 21, 2019. At that time, the Plants were small size in the mother stage. Since then, the Company has grown out the mother plants and successfully taken over 3,000 clones which are now at various stages of development, and thousands of more cuttings are expected to be made over the next few weeks. The initial harvest is expected to be in September 2019, with sales commencing shortly thereafter. The Company’s perpetual production cycle has our team harvesting a new crop every two weeks, and will be at full production by year-end.

As established with our streaming partner, Auxly Cannabis Group Inc. (“Auxly”) will purchase 50% of the production. Lotus has a number of options on dealing with the other 50% of production, including but not limited to, Auxly buying the remaining 50% not allocated to them, at the higher/market price than the fixed price committed on the portion Lotus has pre-sold to Auxly.

Current Licences Held:

On March 8, 2019 Lotus received its Standard Cultivation, Sale for Medical Purposes and Plant/Seeds sales licences pursuant to the Cannabis Act (the “Act”). Under the Act, a Standard Cultivation licence permits the sale of bulk cannabis to federal licence holders with a Processing licence. Under the Act, a Sale for Medical Purposes licence permits the sale of dried cannabis to medical patients who have registered directly with a federal licence holder.

The Plant/Seeds sales licence (the “Offerings”) permits the Company to sell both Offerings to provincially/territorially authorized distributors and/or retailers. The Company is currently in the process of obtaining its Processing licence (which permits the sale of cannabis to provincial distributors).

Facility Expansion:

The Company’s expansion facility design was submitted for building permits at the Township. The building will have an expected production yield of more than double the initial facility. The expansion will use the same low-cost of production design, and will include a dedicated space for in-house extraction and genetic breeding.

Significant Milestones Achieved:

  • Raised over $17MM through equity private placements. The Company has no current debt. Auxly Cannabis Group Inc. subscribed for $5MM in equity common shares – Lotus was one of Auxly’s original streaming partners and signed a definitive offtake agreement, where Auxly has committed to purchase 50% of cultivation from the initial facility.
  • Designed, constructed and commissioned a brand-new 22,500 square foot indoor production facility on its wholly-owned 23-acre property that was purchased for $1.1MM. The Facility is expected to yield 2,000kg of premium cannabis per year.
  • Received Cultivation, Medical and Plant/Seeds sales licences from Health Canada in under 30 days from submitting its Evidence Package – One of the fastest in the industry to do so. Lotus also brought in 3,500 seeds and 229 premium strains through the previous medical regime, which are expected to command higher-end margins.

Corporate Matters:

Lotus welcomes the addition of Jeff Tung (Auxly) to the board and the board has approved a grant of options under the Company’s Incentive Plan to key members of the Lotus Team. The ten-year options at an exercise price of $0.20 are in the amounts of 820,000 to the CEO, 320,000 to the COO, 150,000 to the remaining directors and CFO, and 100,000 to various operations staff.

Lotus Ventures Inc.
“Dale McClanaghan”
Dale McClanaghan, President and CEO

About Lotus Ventures Inc.
Lotus Ventures Inc. (CSE:J) is an Okanagan-based licensed producer focused on growing premium cannabis products for the medical and recreational connoisseur market. Lotus operates an innovative growing facility with access to unique proven strains, and an entirely handcrafted production process created by one of the regions most experienced growing teams.

Click here to connect with Lotus Ventures Inc (CSE:J) for an Investor Presentation.

Source: www.newswire.ca

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less